Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00520741 · ClinicalTrials.gov registry record · Phase 3
Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures
A Phase 3 study of Epilepsy, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 426
- Enrollment target
- 20
- Study locations
NCT00520741: Completed Phase 3 study of Epilepsy, sponsored by UCB Biosciences.
NCT00520741 is a Phase 3 study of Epilepsy that has completed, run by UCB Biosciences. The registered enrollment target is 426 participants, below the 950-participant average among 160 other Epilepsy trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00520741, a Phase 3 study of Epilepsy, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 426 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this historical-controlled trial is to demonstrate the efficacy and safety of conversion to Lacosamide monotherapy in subjects with Partial-onset Seizures who are withdrawn from 1 to 2 marketed antiepileptic drugs.
Primary Outcome
Pre-defined exit criteria: 1. A 2-fold or greater increase in average monthly (28-day) partial seizure frequency (motor and non-motor) compared to average monthly partial seizure frequency (motor and non-motor) during the Baseline Phase 2. A 2-fold or greater increase in consecutive 2-day partial seizure frequency (motor and non-motor) versus the highest consecutive 2-day partial seizure frequency (motor and non-motor) that occurred during the Baseline Phase. Note: if the highest consecutiv
Conditions Studied
Interventions
- DRUG Lacosamide
Study Locations (20)
California
- 120 - La Habra
- 156 - Loma Linda
- 59 - Los Angeles
- 76 - Los Angeles
- 45 - Newport Beach
- 21 - Santa Monica
- 107 - Torrance
Arizona
- 14 - Phoenix
- 151 - Phoenix
- 9 - Phoenix
- 150 - Sun City
- 103 - Tucson
Alabama
- 48 - Alabaster
- 10 - Birmingham
- 18 - Huntsville
- 42 - Northport
Arkansas
- 102 - Jonesboro
- 7 - Little Rock
- 86 - Little Rock
Colorado
- 60 - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
What the finished NCT00520741 record still lists
NCT00520741 is an interventional study that assigns participants to a tested intervention. The registered 426 participants enrollment target is mid-sized for trials with a published cap, below the 950-participant average among 160 other Epilepsy trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Lacosamide is the first listed.
NCT00520741 names 20 study sites across 5 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00520741 about?
NCT00520741 is a clinical study titled "Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures". The objective of this historical-controlled trial is to demonstrate the efficacy and safety of conversion to Lacosamide monotherapy in subjects with Partial-onset Seizures who are withdrawn from 1 to 2 marketed antiepileptic drugs.
What is the current status of trial NCT00520741?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 426 participants. The study started on 2007-08. Estimated completion is 2012-12.
What conditions does trial NCT00520741 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00520741?
The interventions under investigation include: Lacosamide (DRUG).
Who is sponsoring clinical trial NCT00520741?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00520741 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00520741's enrollment target sits among peer trials
426 16th of 160 higher than 145 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
RECRUITING · Phase 3
-
Lemborexant Treatment of Insomnia Linked to Epilepsy
RECRUITING · Phase 3
-
RNS System NAUTILUS Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
COMPLETED · Phase 3
-
Clobazam in Patients With Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
Pediatric Epilepsy Study
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06790784 · 426 participants · Phase 3
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
- NCT04265430 · 425 participants · Phase 4
Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors
- NCT04278690 · 425 participants · NA
Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit
- NCT05321368 · 425 participants · NA
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia